Trials / Unknown
UnknownNCT02231138
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease：a Multicentre Open Study
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,600 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease. The purpose of this study is to evaluate the safety and efficacy of Abelmoschus manihot for treating chronic kidney disease in large scale samples with long time take.
Detailed description
The test has not been completed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abelmoschus manihot (AM) | Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot. |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2016-01-01
- Completion
- 2016-12-01
- First posted
- 2014-09-04
- Last updated
- 2016-06-01
Locations
78 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02231138. Inclusion in this directory is not an endorsement.